Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cephalostatin analogues--synthesis and biological activity.
Flessner T, Jautelat R, Scholz U, Winterfeldt E. Flessner T, et al. Among authors: jautelat r. Fortschr Chem Org Naturst. 2004;87:1-80. doi: 10.1007/978-3-7091-0581-8_1. Fortschr Chem Org Naturst. 2004. PMID: 15079895 Review.
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.
Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schäfer M, Briem H, Schulze J, Hillisch A, Reichel A, Wengner AM, Siemeister G. Lücking U, et al. Among authors: jautelat r. ChemMedChem. 2013 Jul;8(7):1067-85. doi: 10.1002/cmdc.201300096. Epub 2013 May 13. ChemMedChem. 2013. PMID: 23671017
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP. Follmann M, et al. Among authors: jautelat r. J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021/acs.jmedchem.7b00449. Epub 2017 Jun 12. J Med Chem. 2017. PMID: 28557445 Free article.
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
Schulze VK, Klar U, Kosemund D, Wengner AM, Siemeister G, Stöckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Holton SJ, Briem H, Marquardt T, Schirok H, Jautelat R, Bohlmann R, Nguyen D, Fernández-Montalván AE, Bömer U, Eberspaecher U, Brüning M, Döhr O, Raschke M, Kreft B, Mumberg D, Ziegelbauer K, Brands M, von Nussbaum F, Koppitz M. Schulze VK, et al. Among authors: jautelat r. J Med Chem. 2020 Aug 13;63(15):8025-8042. doi: 10.1021/acs.jmedchem.9b02035. Epub 2020 Apr 27. J Med Chem. 2020. PMID: 32338514
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B. Sommer A, et al. Among authors: jautelat r. Cancer Res. 2016 Nov 1;76(21):6331-6339. doi: 10.1158/0008-5472.CAN-16-0180. Epub 2016 Aug 19. Cancer Res. 2016. PMID: 27543601
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
Vakalopoulos A, Wunder F, Hartung IV, Redlich G, Jautelat R, Buchgraber P, Hassfeld J, Gromov AV, Lindner N, Bierer D, Gries J, Kroh W, Paulsen H, Mittendorf J, Lang D, Becker-Pelster E, Brockschnieder D, Geiss V, Li V, Straub A, Knorr A, Mondritzki T, Trübel H, Raschke M, Schaefer M, Thomas D, Sandner P, Stasch JP, Follmann M. Vakalopoulos A, et al. Among authors: jautelat r. J Med Chem. 2023 Jun 8;66(11):7280-7303. doi: 10.1021/acs.jmedchem.2c02082. Epub 2023 Apr 11. J Med Chem. 2023. PMID: 37040336
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Willuda J, Linden L, Lerchen HG, Kopitz C, Stelte-Ludwig B, Pena C, Lange C, Golfier S, Kneip C, Carrigan PE, Mclean K, Schuhmacher J, von Ahsen O, Müller J, Dittmer F, Beier R, El Sheikh S, Tebbe J, Leder G, Apeler H, Jautelat R, Ziegelbauer K, Kreft B. Willuda J, et al. Among authors: jautelat r. Mol Cancer Ther. 2017 May;16(5):893-904. doi: 10.1158/1535-7163.MCT-16-0474. Epub 2017 Mar 14. Mol Cancer Ther. 2017. PMID: 28292941
Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.
Collin MP, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H. Collin MP, et al. Among authors: jautelat r. ChemMedChem. 2018 Mar 6;13(5):437-445. doi: 10.1002/cmdc.201700718. Epub 2018 Feb 16. ChemMedChem. 2018. PMID: 29451369
12 results